LSD | 25166-07-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: LSD
• 英文别名: l-Isolysergic acid diethylamide；(6aS,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• CAS: 25166-07-8
• 化学式: C₂₀H₂₅N₃O
• 分子量: 323.438
• InChiKey: VAYOSLLFUXYJDT-KDOFPFPSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  39.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (6aR,9R)-7-甲基-4,6,6a,7,8,9-六氢-吲哚并[4,3-fg]喹啉-9-甲酰肼 在 盐酸 、 sodium nitrite 作用下， 生成 异麦角酰二乙胺 、 LSD
  参考文献：
  名称：

  立体异构麦角麦角酸和二氢麦角麦角酸的酰胺。38.关于麦角生物碱的交流

  摘要：

  描述了麦芽糖酸，异麦角酸，二氢麦角酸（I）和二氢异麦角酸（I）与伯胺和仲胺的大量酰胺酰胺类衍生物的存在和性质。

  DOI：

  10.1002/hlca.19550380207

文献信息

• [EN] PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE PSILOCINE EN TANT QU'AGENTS SÉROTONINERGIQUES SÉROTONINERGIQUES POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：MINDSET PHARMA INC

  公开号：WO2021155470A1

  公开（公告）日：2021-08-12

  The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. (I)

  本申请涉及公式（I）的哌嗪酮衍生物，以及其制备方法、包含它们的组合物以及它们在细胞中激活5-羟色胺受体的使用，以及通过激活细胞中的5-羟色胺受体治疗疾病、障碍或病况。 (I)
• [EN] 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE 3-PYRROLIDINE-INDOLE EN TANT QU'AGENTS PSYCHÉDÉLIQUES SÉROTONINERGIQUES POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：MINDSET PHARMA INC

  公开号：WO2021155467A1

  公开（公告）日：2021-08-12

  The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions. Formula (I)

  本申请涉及一般式（I）的3-环氨基吲哚衍生物，以及它们的制备方法、包含它们的组合物和它们在细胞中激活5-羟色胺受体以及通过激活细胞中的5-羟色胺受体治疗疾病、障碍或病况的用途。这些疾病、障碍或病况包括精神病、精神疾病和其他神经疾病、障碍和病况。式（I）：
• [EN] 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS D'AMINE-INDOLE 3-CYCLIQUE UTILISÉS EN TANT QU'AGENTS SÉROTONERGIQUES POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：MINDSET PHARMA INC

  公开号：WO2022120475A1

  公开（公告）日：2022-06-16

  The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, and treating diseases, disorders or conditions treatable by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis and mental illness. (Formula (I))

  本申请涉及一般式(I)的3-环氨基吲哚衍生物，其制备过程，包含它们的组合物以及它们在细胞中激活5-羟色胺受体和治疗可通过细胞中5-羟色胺受体激活治疗的疾病、失调或病症的用途。这些疾病、失调或病症包括精神病和精神疾病。(式(I))
• 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
  申请人：Mindset Pharma Inc.

  公开号：US20220017550A1

  公开（公告）日：2022-01-20

  The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.
• PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
  申请人：Mindset Pharma Inc.

  公开号：US20220017549A1

  公开（公告）日：2022-01-20

  The present application relates to psilocin derivatives of Formula (1), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.